GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short

Published 2 weeks ago Negative
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
Auto
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

Continue Reading

View Comments

More News

Bitcoin (BTC) Loses $100,000, Ripple Holders Refuse to Sell, Franklin Templeton’s XRP ETF to Get Approval, DOGE Risks Adding Zero – Top Weekly Crypto News

1 hour ago Negative

23% of Warren Buffett's $257 Billion Portfolio for 2026 Is Invested in These 2 Unstoppable Stocks

1 hour ago Positive

Stock market today: Dow, S&P 500, Nasdaq futures rise with government shutdown in sharp focus

1 hour ago Positive

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Ea

2 hours ago Negative

Avance Clinical, ‘신장 및 심대사 질환 우수 센터’ 설립하며 환자 모집 최적화 통해 임상시험 성공률 제고에 박차

2 hours ago Neutral